BRAUN
11.5.2021 09:02:07 CEST | Business Wire | Press release
Braun celebrates its 100th anniversary in 2021 and we are pleased to announce the 21st BraunPrize International Design Competition, with a virtual awards ceremony due to take place in October 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005118/en/
Established in 1968, the BraunPrize was Germany’s first international competition with the aim to promote the work of young designers. Braun’s continuous commitment to this cause has been highly regarded by the design world and the design-aware public ever since.
This year, young, up-and-coming designers and inventors will be tasked with exploring good design to address and solve the challenges of today and tomorrow; and Braun’s commitment to nurturing young talent will see this year’s total prize value increase to $100,000 USD.
A recent global study, conducted by Braun of 18-25 year olds, revealed that Gen Z believes that good design will play a pivotal role in its future. In fact, 4 out of 5 (78%) agreed that accessibility—regardless of age, impairments or skill level—and ease of use are the single most important areas in which design can deliver an impactful change. Simple and useful design means good design for everyone—design that anyone can understand and anyone can make use of to better their life and to better our collective future.
Braun has shaped the past, present and future with ‘good design’. Braun believes that good design follows the principles of ‘Simple, Useful and Built to last,’ and that these design tenents remain as relevant in 2021 as they were in 1921 in making life better for people and the environment. Braun knows that the next 100 years will be shaped through the power of ‘good design’ for our collective benefit, so the 2021 BraunPrize International Design Competition will challenge creative minds to help shape tomorrow.
Oliver Grabes, Head of Braun Design and Chairman of the BraunPrize commented:
“The 2021 BraunPrize International Design Competition challenge is an opportunity for young designers, inventors and students to identify design ideas and visionary concepts that will help promote behavioral change and make an impact on today’s society and the future of our planet. Design that can effect this type of positive social impact is good design at its best.
Oliver continued: “We are really excited by this year’s competition and encourage you to help us shape tomorrow. 2018 saw more submissions than ever, with 3,087 entrants from 107 counties, making it a record year for the BraunPrize. We can’t wait to see what the 2021 BraunPrize International Design Competiton will unearth.”
For more information, please visit www.uk.braun.com/en-gb/braunprize or on Instagram @braunprize.
THE 2021 BRAUN PRIZE INTERNATIONAL DESIGN COMPETITION DETAILS
THE 2021 CHALLENGE: SHAPE TOMORROW
A call to action to help shape tomorrow. A forum for young designers, inventors and students with a commitment to exploring good design to address and solve the challenges of today and tomorrow.
WHO IS ELIGIBLE
The 2021 BraunPrize International Design Competition is open globally and is free to enter. Submissions are welcome from young designers and inventors with less than 5 years work experience and students of any profession.
PRIZE MONEY
The BraunPrize International Design Competition will award $100,000 USD in prize money.
JURY PANEL
The 2021 BraunPrize Internation Design Competition Jury Panel will comprise of international design leaders from across the globe.
SUBMISSION
Submissions for the 2021 BraunPrize International Design Competition will open in July 2021 and the BraunPrize Winner announcements will take place in October 2021.
NOTES TO EDITORS
- The BraunPrize was established in 1968
- The BraunPrize 2021 marks the 21st edition of the international design competition
- In 2018, the BraunPrize received 3,087 entries from 107 countries
- The BraunPrize 2021 is organized by Braun, a Procter & Gamble brand, and managed by the Braun Design Team in Kronberg, Germany
- Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to hair care appliances. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom